Trials / Completed
CompletedNCT00795418
Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients
A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mid Alzheimer's disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo | Placebo comparator |
| BIOLOGICAL | CAD106 |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2010-11-01
- First posted
- 2008-11-21
- Last updated
- 2020-12-17
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00795418. Inclusion in this directory is not an endorsement.